Eli Lilly's Foundayo Preserves 75% of Weight Loss After GLP-1 Injections End
Updated
Updated · case.edu · Jun 22
Eli Lilly's Foundayo Preserves 75% of Weight Loss After GLP-1 Injections End
3 articles · Updated · case.edu · Jun 22
Summary
A new study found Eli Lilly's Foundayo helped patients keep about 75% of the weight they had lost after stopping injectable GLP-1 drugs such as Wegovy or Zepbound.
GLP-1 pills could offer a more convenient, lower-cost follow-on option than injections, according to Case Western Reserve University's Betul Hatipoglu, though the benefit appears to be partial rather than full weight-loss maintenance.
Hatipoglu said pill-based GLP-1 treatment can also bring gastrointestinal side effects, underscoring that post-injection obesity care still needs to be tailored to individual patients.